Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Proteome-based plasma biomarkers for Alzheimer's disease.

Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S.

Brain. 2006 Nov;129(Pt 11):3042-50.

3.

Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.

Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S.

J Neurol. 2008 Nov;255(11):1712-20. doi: 10.1007/s00415-008-0006-8. Epub 2008 Aug 1.

PMID:
19156487
4.

Proteome studies of CSF in AD patients.

Davidsson P, Sjögren M.

Mech Ageing Dev. 2006 Feb;127(2):133-7. Epub 2005 Nov 15.

PMID:
16293296
5.

The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.

Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P.

Biomarkers. 2008 Sep;13(6):618-36. doi: 10.1080/13547500802445199 .

PMID:
18830857
6.

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, Kellmann M, Mullen W, Eichenlaub M, Mischak H, Wiedemann K.

PLoS One. 2011;6(10):e26540. doi: 10.1371/journal.pone.0026540. Epub 2011 Oct 26.

7.

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.

Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J.

Brain. 2006 May;129(Pt 5):1177-87. Epub 2006 Apr 6.

8.

Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study.

Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJ.

J Alzheimers Dis. 2014;38(3):515-31. doi: 10.3233/JAD-130380. Review.

PMID:
24121966
9.

Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.

Shield-Artin KL, Bailey MJ, Oliva K, Liovic AK, Barker G, Dellios NL, Reisman S, Ayhan M, Rice GE.

Proteomics Clin Appl. 2012 Apr;6(3-4):170-81. doi: 10.1002/prca.201100008.

PMID:
22532453
10.

Recent cerebrospinal fluid biomarker studies of Alzheimer's disease.

Choi YS, Choe LH, Lee KH.

Expert Rev Proteomics. 2010 Dec;7(6):919-29. doi: 10.1586/epr.10.75. Review.

PMID:
21142892
11.

Can apolipoproteins and complement factors be biomarkers of Alzheimer's disease?

Manral P, Sharma P, Hariprasad G, Chandralekha, Tripathi M, Srinivasan A.

Curr Alzheimer Res. 2012 Oct;9(8):935-43.

PMID:
22631439
12.

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P.

Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):140-6.

PMID:
14559363
13.

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Jun;119(6):669-78. doi: 10.1007/s00401-010-0667-0. Epub 2010 Mar 16.

14.

Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.

Jung SM, Lee K, Lee JW, Namkoong H, Kim HK, Kim S, Na HR, Ha SA, Kim JR, Ko J, Kim JW.

Neurosci Lett. 2008 May 9;436(2):153-7. doi: 10.1016/j.neulet.2008.03.010. Epub 2008 Mar 18.

PMID:
18378077
15.

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J.

J Alzheimers Dis. 2006 Aug;9(3):293-348.

PMID:
16914840
16.

Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study.

Zabel M, Schrag M, Mueller C, Zhou W, Crofton A, Petersen F, Dickson A, Kirsch WM.

J Alzheimers Dis. 2012;30(2):311-21. doi: 10.3233/JAD-2012-112012.

17.

Serum biomarkers for Alzheimer's disease: proteomic discovery.

German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP.

Biomed Pharmacother. 2007 Aug;61(7):383-9. Epub 2007 Jun 18.

PMID:
17614251
18.

Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Liu Y, Qing H, Deng Y.

Int J Mol Sci. 2014 May 6;15(5):7865-82. doi: 10.3390/ijms15057865. Review.

19.

Mining biomarkers in human sera using proteomic tools.

Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, Kupchak P, Kireeva I, Ingratta L, Jackowski G.

Proteomics. 2004 Jan;4(1):244-56.

PMID:
14730686
20.

Blood-based proteomics for personalized medicine: examples from neurodegenerative disease.

Goldknopf IL.

Expert Rev Proteomics. 2008 Feb;5(1):1-8. doi: 10.1586/14789450.5.1.1. No abstract available.

PMID:
18282116
Items per page

Supplemental Content

Write to the Help Desk